Arcadia Investment Management Corp MI Sells 1,452 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Arcadia Investment Management Corp MI cut its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 56.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,109 shares of the company’s stock after selling 1,452 shares during the quarter. Arcadia Investment Management Corp MI’s holdings in IDEXX Laboratories were worth $459,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Angeles Wealth Management LLC lifted its position in IDEXX Laboratories by 2.4% in the third quarter. Angeles Wealth Management LLC now owns 1,078 shares of the company’s stock worth $545,000 after buying an additional 25 shares during the last quarter. Cranbrook Wealth Management LLC lifted its position in IDEXX Laboratories by 7.0% in the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company’s stock worth $158,000 after buying an additional 25 shares during the last quarter. Perigon Wealth Management LLC lifted its position in IDEXX Laboratories by 1.8% in the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company’s stock worth $632,000 after buying an additional 26 shares during the last quarter. Summit Trail Advisors LLC lifted its position in IDEXX Laboratories by 3.3% in the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company’s stock worth $335,000 after buying an additional 26 shares during the last quarter. Finally, First Horizon Advisors Inc. lifted its position in IDEXX Laboratories by 4.0% in the third quarter. First Horizon Advisors Inc. now owns 704 shares of the company’s stock worth $356,000 after buying an additional 27 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Performance

IDXX stock opened at $452.89 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The business has a 50-day moving average price of $431.19 and a 200 day moving average price of $452.42. The company has a market capitalization of $37.09 billion, a P/E ratio of 42.45, a PEG ratio of 3.39 and a beta of 1.37. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39.

Analysts Set New Price Targets

A number of brokerages recently issued reports on IDXX. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Morgan Stanley decreased their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Barclays lifted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Finally, Leerink Partners began coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average target price of $533.75.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,330 shares of company stock worth $6,161,276 over the last three months. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.